Source comparison
Best CJC-1295 no DAC & Ipamorelin for Synergistic GH Release: Protocol Comparison
Research applications vary widely, but most peptide studies testing GH secretagogue synergy follow one of three core protocols. The table below compares dosing, timing, and typical use cases. Acute GH Pulse Study 100 mcg 200 mcg Single dose Fasted AM or pre-sl
This comparison does not assign a generated winner or score.
- Research applications vary widely, but most peptide studies testing GH secretagogue synergy follow one of three core protocols. The table below compares dosing, timing, and typical use cases.
- Acute GH Pulse Study
- 100 mcg
- 200 mcg
- Single dose
- Fasted AM or pre-sleep
- Measuring peak GH response and AUC in controlled settings
- Best for short-term kinetics and establishing baseline GH secretion capacity
- Moderate Frequency Protocol
- 100–150 mcg
- 200–250 mcg
- 1–2× daily
- AM fasted + optional pre-sleep
- Investigating sustained effects on IGF-1 elevation and anabolic markers over 4–12 weeks
- Most commonly cited in peptide research literature; balances GH stimulation with receptor sensitivity
- High Frequency Protocol
- 300 mcg
- 2–3× daily
- AM, post-training, pre-sleep
- Examining maximal GH output in recovery or performance contexts
- Requires careful monitoring for receptor desensitization; not suitable for long-term continuous use
- Acute GH pulse protocols are the standard for pharmacokinetic studies. A single dose of CJC-1295 no DAC and Ipamorelin allows researchers to isolate the GH response curve without confounding variables from prior doses. Blood draws at 15, 30, 60, and 120 minutes post-injection capture the full secretion and clearance arc, providing data on peak GH concentration, time to peak, and area under the curve. This protocol is particularly useful when comparing batches or establishing dose-response relationships.
- Moderate frequency protocols represent the most sustainable approach for longer research timelines. Administering the stack once or twice daily maintains elevated GH pulses without driving continuous receptor occupancy. Studies examining body composition changes, IGF-1 elevation, or metabolic markers typically use this framework across 8–12 week observation periods. The trade-off is slower cumulative GH exposure compared to high-frequency protocols, but with lower risk of tachyphylaxis (receptor desensitization). Our small-batch synthesis model ensures researchers can source CJC-1295 no DAC and Ipamorelin in consistent batches across multi-week protocols without batch-to-batch variability.
- High frequency protocols push the upper boundary of GH secretagogue dosing. Three daily administrations maximize cumulative GH exposure but also increase the risk of receptor downregulation. Research teams using this approach typically cycle the peptides—4–6 weeks on, 2–4 weeks off—to allow receptor sensitivity to recover. This protocol is less common in long-term studies and more typical in performance or recovery research contexts where short-term maximal GH output is the variable of interest.